GSTM1 tissue genotype as a recurrence predictor in nonmuscle invasive bladder cancer

Journal of Korean Medical Science

Volumn 26, Issue 2, 2011, Pages 231-236

  Ha, Yun Sok ^a   Yan, Chunri ^a,b   Jeong, Pildu ^a   Kim, Won Tae ^a   Yun, Seok Joong ^a   Kim, Isaac Yi ^c   Moon, Sung Kwon ^d   Kim, Wun Jae ^a,b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d Chungju National University   (South Korea)

Author keywords

Biological; Glutathione S transferase T1; GSTM1; Tumor markers; Urinary bladder neoplasms

Indexed keywords

GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; ISOENZYME; TUMOR MARKER;

AGED; ARTICLE; BLADDER TUMOR; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE;

AGED; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79551657206     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.2.231     Document Type: Article

References (30)

1. Hirao Y, Kim WJ, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol 2009; 19: 494-9.
2. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003; 15: 227-33.
3. Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, Kim WJ, Yun SJ. Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci 2009; 24: 468-73.
4. Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, Lee SC, Kim WJ. mRNA Expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer. Korean J Urol 2010; 51: 15-20.
5. Kim WJ, Lee HL, Lee SC, Kim YT, Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 2000; 164: 209-13.
6. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione Stransferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 3915-25.
7. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 2009; 32: 416-23.
8. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N; EPICURO/Spanish Bladder Cancer Study investigators. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010; 57: 283-92.
9. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87: 13-5.
10. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. International Histologic Classification of Tumors. Geneva: World Health Organzation; 1973.
11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J; European Association of Urology (EAU). EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14.
12. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30.
13. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25.
14. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347: 295-7.
15. Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, Katoh T. GSTT1-null genotype is a protective factor against bladder cancer. Urology 2002; 60: 913-8.
16. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159-64.
17. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999; 5: 4079-84.
18. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265-8.
19. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829-34.
20. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008; 180: 1141-5.
21. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC. Predictive value of progressionrelated gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010; 9: 3.
22. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-25.
23. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, Moon SK, Choi YH, Kim WJ. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010; 16: 2131-7.
24. Ha YS, Yan C, Park C, Yun SJ, Moon SK, Choi YH, Kim WJ. GSTT1: A marker of the aggressiveness of bladder cancer. Urol Int 2010. doi: 10.1159/000321689.
25. Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol 2005; 48: 339-44.
26. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30.
27. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 1641-4.
28. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004; 172: 70-5.
29. Ramani VA, Bromage SJ, Clarke NW. A contemporary standard for morbidity and outcome after radical cystectomy. BJU Int 2009; 104: 628-32.
30. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organconfined TCC at radical cystectomy. Eur Urol 2007; 51: 152-60.